A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Inclusion Criteria:

• Participant has systemic autoimmune rheumatic diseases associated interstitial lungdiseases (SARD-ILD), defined as

• Diagnosis by a rheumatologist (or equally qualified medical physician) with atleast 1 of the following SARDs: Rheumatoid arthritis (RA), systemic sclerosis (SSc) (participants must be anticentromere auto-antibody negative), idiopathicinflammatory myopathy (IIM), Sjögren's disease, or mixed connective tissuedisease (MCTD) (participants must be anti-U1-ribonucleoprotein particle (RNP)auto-antibody positive)

• Presence of fibrotic interstitial lung disease (ILD) on high-resolutioncomputed tomography (HRCT), defined as presence of reticular abnormality withtraction bronchiectasis with or without honeycombing (HC), with disease extent >10% on HRCT performed within 12 months of Visit 1 or, if historical scan isnot available, on baseline HRCT taken prior to Visit 2, as confirmed by centralreview

• No lung function improvement and no clinically significant ILD improvement as atreatment response to immunosuppressant (IS) therapy according to both criteria:

• No improvement in absolute forced vital capacity (FVC) % predicted >5% withinthe 15 months prior to Visit 1, as measured by 2 spirometry assessments thatmust be ≥3 months apart. (Note: 1: In the case of multiple PFTs over the 15months prior to screening, exceptional values of absolute change in FVC %predicted >5% are acceptable if the overall trend of FVC % predicted isdeclining or stable; note 2: Visit 1 spirometry may be used to fulfill theinclusion criterion if there is only 1 spirometry reading in the 15 monthsprior to Visit 1)

• No clinically significant improvement in ILD based on clinician's judgement (including symptoms, imaging/HRCT, or other assessments as considered relevantand documented by the Investigator)

• FVC ≥45% of predicted normal at Visit 1

• Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normalcorrected for haemoglobin (Hb) within 3 months prior to or at Visit 1

• Participants must be on stable treatment with any IS agent for ≥6 months (or ≥3months for participants with IIM-ILD) prior to visit 2, with the followingspecifications:

• If using prednisone, participants must be on stable dose for ≥4 weeks prior toVisit 2

• If using rituximab, participants must have completed their first cycle >6months prior to Visit 2

• If using nintedanib, participants must be on a stable dose for ≥12 weeks prior toVisit 2

• In the opinion of the Investigator, no change in background standard of care (SoC)treatment with immunosuppressant (IS), immunomodulator (IM), or nintedanib isplanned

• Further inclusion criteria apply

Exclusion Criteria:

• Organising pneumonia as predominant pattern in the HRCT

• Prebronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) <0.7 at Visit 1

• Acute ILD exacerbation within 3 months prior to Visit 1 and/or during the screeningperiod, based on Investigator judgement

• Active vasculitis, unstable or uncontrolled within 8 weeks prior to Visit 1 orduring the screening period

• Any suicidal behaviour in the past 2 years

• Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past 3 months or at Visit 1, and/or at Visit 2

• Use of any of the following medications: cyclophosphamide within 6 months of Visit 1, pirfenidone within 8 weeks of Visit 1

• Further exclusion criteria apply